Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.

Journal of gastroenterology - 1 Mar 2026

Inada Hiroki, Kurano Sotaro, Miyamoto Hideaki, Onishi Masaya, Suzuki Yutaka, Narahara Satoshi, Otsuka Fumiya, Iio Etsuko, Watanabe Takehisa, Setoyama Hiroko, Nagaoka Katsuya, Beppu Toru, Hayashi Hiromitsu, Tanaka Yasuhito

Abstract excerpt

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although immune checkpoint inhibitor (ICI)-based chemotherapy has recently been introduced as a first-line treatment, clinical responses remain highly variable. Currently, no reliable molecular biomarkers are available to predict the therapeutic efficacy of ICC. METHODS: We conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Cholangiocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to Immune Checkpoint Inhibitors

Share to Progression-Free Survival

Share to Tumor Microenvironment

Source

Identifiers

PMID: 41247518
DOI: 10.1007/s00535-025-02320-1

Genes

TP53
CD109
TAP1
TAP2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.PMID 41247518Read ↗

Molecular Profile of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Mutational landscape of intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Comprehensive Analysis of Genomic Mutation Signature and Tumor Mutation Burden for Prognosis of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Molecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation.Semantic proximity Read ↗

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSemantic proximity Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for InterventionSemantic proximity Read ↗

The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations.Semantic proximity Read ↗

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.